Pivotal Announces Scientific Presentation at the 17th World Congress on Heart Disease Demonstrating Superiority of VASCAZEN™ Unique Formulation

Pivotal Announces Scientific Presentation at the 17th World Congress on Heart Disease Demonstrating Superiority of VASCAZEN™ Unique Formulation PR Newswire WOODBRIDGE, Ontario, August 9, 2012 WOODBRIDGE, Ontario, August 9, 2012 /PRNewswire/ -- Pivotal Therapeutics Inc. (OTCQX:PVTTF) (CNSX:PVO), a specialty pharmaceutical company with a focus on cardiovascular health, is pleased to announce that data from a scientific study related to the company's product VASCAZEN™ concluded that highly purified Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) with a 6:1 ratio caused potent endothelium- dependent relaxations of isolated blood vessels, relaxations superior to that of other pure EPA:DHA ratios (1:1) and only 100% EPA or only 100% DHA. The study authored by F. Zgheel, M. Alhosin, C. Auger and V.B. Schini-Kerth, entitled The highly purified EPA:DHA 6:1 product evokes potent endothelium-dependent relaxations of porcine coronary artery rings via the redox-sensitive PI3-kinase/Akt-dependent phosphorylation of theNOS was presented at the 17 World Congress on Heart Disease - Annual thScientific Sessions 2012 on July 29 in Toronto, Canada and will be presented at the European Society of Cardiology (ESC) in Munich, Germany on August 27, 2012.